At the 24th World Congress of Dermatology in Milan, June 10-15, 2019, Kymab’s Senior Medical Director Dr Porter-Brown presented data showing that Kymab’s novel anti-OX40L monoclonal antibody, with potential in atopic dermatitis, demonstrates acceptable safety and tolerability profiles. The results support development of KY1005 in immune-mediated diseases, such as AD, and a phase 2a study is under way.
At the 24th World Congress of Dermatology in Milan, June 10-15, 2019, Kymab’s Senior Medical Director Dr Porter-Brown presented data showing that Kymab’s OX40L-blocking monoclonal antibody KY1005 strongly suppresses the delayed-type hypersensitivity skin response to KLH in healthy volunteers. A phase 2a study in moderate to severe atopic dermatitis is under way.
At the 24th European Hematology Association’s Annual Congress 2019 in Amsterdam, Netherlands, June 15, Kymab will deliver an oral presentation on pre-clinical evaluation of KY1049, Kymab’s proprietary FVIII mimetic antibody Abstract: S851
At the 24th European Hematology Association’s Annual Congress 2019 in Amsterdam, Netherlands, June 14, Kymab will present a poster on development of KY1049 using Kymab’s proprietary Intelliselect Bispecific Platform which can efficiently generate diverse and extensive panels of fully human, common light chain bispecific antibodies. Abstract: PF338 at https://library.ehaweb.org/.
At the June 2019 American Society of Clinical Oncology (ASCO) Kymab has an abstract on an ongoing first-in-human study of KY1044, a fully human anti-ICOS IgG1 antibody as monotherapy and in combination with atezolizumab in patients with selected advanced malignancies.
At the April 2019 European Laboratory Research & Innovation Group (ELRIG) – Research & Innovations, Kymab presented data on the development of innovative assays for testing of our therapeutic antibodies, including work conducted using macrophage-like cell lines for high-throughput screening of molecules able to modulate macrophage function.
At the April 2019 European Laboratory Research & Innovation Group (ELRIG) – Research & Innovations, Kymab presented results describing the development of an imaging-based T-cell infiltration assay, a model that can be multiplexed with tumour killing and activation as readouts and has the potential to be used to screen drug candidates while enabling a better understanding of the complex biology of the tumour microenvironment.
At the April 2019 American Association for Cancer Research Annual meeting, Kymab translational science activities reveal solid tumours, such as oesophageal cancer, cervical cancer, non-small cell lung cancer and others, that are infiltrated with high numbers of ICOS-positive regulatory T-cells. The combination of transcriptomic analysis and IHC can be used to differentiate such tumours: KY1044 is in phase 1/2 study assessing its safety and efficacy as a single agent and in combination.
Published in Nature Metabolism on 7 January 2019, the paper by Professor Igor Theurl, Kymab's Co-Head of Haematology, together with scientists at Dresden University, describes how the Transferrin receptor 2 controls bone mass and pathological bone formation via BMP and Wnt signalling.
At the December 2018 American Society of Hematology Conference Kymab, together with Collaborators from the Department of Internal Medicine at the University of Innsbruck, presented data that showed that anti-BMP6 antibody KY1070 worked synergistically with erythropoietin in two different models of anaemia of chronic disease
Published in The Journal of Infectious Disease on 30 October 2018, the article 'Anatomic and Cellular Niches for Mycobacterium tuberculosis in Latent Tuberculosis Infection' by Stephen Reece, PhD, Kymab's Group Leader, Infectious Diseases and Vaccines, together with other scientists, evaluates literature on M. tuberculosis locations during latency.
At the April 2018 American Association for Cancer Research Annual meeting, Kymab's team show that combining immune checkpoint blockers with the anti-ICOS KY1044 antibody results in a strong tumour response, warranting the assessment of KY1044 in cancer patients in a clinical trial
Kymab's data reports that KY1055, a novel ICOS/PD-L1 bispecific antibody, efficiently enhances T cell activation and delivers a potent anti-tumour response in vivo: the results, presented at the April 2018 American Association for Cancer Research Annual meeting, support development of KY1055 for the treatment of solid tumours
Kymab's data at the November 2017 Society for Immunotherapy of Cancer meeting on its lead immuno-oncology antibody KY1044, showing strong potential for inhibiting tumour growth
View the poster
2017 British Society for Immunology Congress poster showing that T-cells generated by Kymab's co-culture system can provide a suitable setting for evaluation of potential patient responses to immunotherapy
At the 2017 British Society for Immunology Congress, Kymab's team describe a cell-based, in vitro screening cascade to characterise anti-human PD-L 1 antibodies, identifying a lead clone, KY1003, that has the attributes of a clinically relevant PD-L1 antibody
The Kymab team developed a "tumour-educated" T-cell killing assay for predictive in vitro assessment of anti-PD-L1 antibodies: data presented at the 2017 British Society for Immunology Congress shows how KY1003 can revert T-cell exhaustion in in vitro models.
On 20 September 2017, Kymab and Seattle Children’s Research Institute published impressive results in Science Translational Medicine using KY1005 in a model of acute Graft-versus-Host Disease (aGVHD), suggesting an important role in blood-system transplants, such as in the treatment of leukaemia.
Published in Nature Biotechnology on 16 March 2014, the paper by Kymab scientists describes the development of Kymouse, which is able to produce an enormous range of human antibodies that can be developed as potent drugs to treat diseases such as cancer, autoimmune and infectious diseases.